| Characteristic | Average time in days |
|---|---|
| Germany | 174 |
| Switzerland | 232 |
| Serbia | 264 |
| Scotland*** | 265 |
| Slovenia | 277 |
| Bosnia and Herzegovina* | 319 |
| Sweden | 326 |
| Denmark | 333 |
| Finland | 346 |
| Croatia* | 361 |
| England*** | 369 |
| North Macedonia* | 382 |
| Austria | 392 |
| Netherlands | 430 |
| Norway | 441 |
| Belgium | 456 |
| Cyprus | 461 |
| France** | 464 |
| Luxembourg | 476 |
| Italy | 494 |
| Iceland | 498 |
| Ireland | 564 |
| Romania | 595 |
| Czechia | 616 |
| Latvia | 621 |
| Slovakia | 645 |
| Portugal | 687 |
| Greece | 719 |
| Poland | 736 |
| Hungary | 747 |
| Spain | 773 |
| Bulgaria | 786 |
| Estonia | 839 |
| Lithuania | 1,073 |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
May 2025
Europe
As of January 5, 2025
Data collected is for drugs launched from 2020 to 2023. In most countries, availability equates to granting of access to the reimbursement list, except in DK, FI, NO, SE some hospital products are not covered by the general reimbursement scheme. The time to availability (formerly known as length of delay) is the days between EMA marketing authorization and the date of availability to patients.Â
* These countries did not complete a full dataset and therefore availability may be unrepresentative.
** The source mentions that it does not consider France's system of temporary authorization for some products, which means this time will be higher than in reality.
*** MHRA’s Early Access to Medicines Scheme provides access before marketing authorization but is not included within this analysis, and would reduce the overall days for a small subset of medicines.
